PCI Expands Clinical Distribution with New Facility - Release
CLINICAL SERVICES PACKAGER TO EXPAND NORTH AMERICAN OPERATIONS
Packaging Coordinators Inc. (PCI) is pleased to announce it has undertaken construction of a new stand-alone Clinical storage and global distribution facility to support its growing business. PCI plans to break ground this week in anticipation of completing construction in mid-2014. The new state-of-the-art facility will be located in Rockford, Illinois near PCI’s current Clinical packaging, storage, and distribution facility located on the campus of its Rockford commercial pharmaceutical packaging location. The existing facility was constructed in 2011 to support PCI’s strategic expansion of Clinical services for investigational medicines. Business growth in the area of global distribution of investigational products has warranted construction of the new purpose-built facility, allowing PCI to provide additional capacity for both storage and global distribution. The new site complements PCI’s 2012 opening of its European based stand-alone Clinical distribution site in Treforest, Wales located just north of Cardiff in the United Kingdom.
PCI’s new Clinical distribution facility will support ambient and Cold Chain storage of investigational medicines and will be DEA approved for storage of Schedule II-V controlled substances. The new site is designed to be 93,000 square feet and will be located in the industrial park adjacent to the Chicago Rockford International airport at 5775 Logistics Parkway, located near the intersection of Blackhawk Rd. and Falcon Rd. PCI is utilizing the services of Cord Construction for the new facility and McClellan Blakemore are the architects of record for the project. PCI’s proximity to the airport provides convenient international access. PCI currently distributes Clinical/investigational medicines to investigator sites around the world and industry trends demonstrate continued growth of clinical studies being executed in emerging markets such as South America, Asia, Russia, and Eastern Europe.
“We are very excited about the opportunity to build out our distribution capabilities in support of business growth,” states Bob Misher, Senior Vice President of Global Clinical Services at PCI. “The ability to package, store, globally distribute, and process returns of investigational medicines all in one state-of-the-art campus is a real benefit to our clients. This new facility helps us strategically position our business to further support industry trends we are witnessing; the first being international growth in the execution of our clients’ clinical studies, and the second being clients’ investigational medicines needing Cold Chain storage and shipment at 2-8°C, -20°C, and -80°C. We have been steadily expanding our capabilities in these areas as industry dynamics change. The location is built to be very accommodating as the industry and the needs of our clients evolve in years to come.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
